Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cozma, L. S.
Right arrow Articles by Owens, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cozma, L. S.
Right arrow Articles by Owens, D. R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 28:1001-1007, 2005
© 2005 by the American Diabetes Association, Inc.

Clinical Care/Education/Nutrition
Original Article

ß-Cell Response During a Meal Test

A comparative study of incremental doses of repaglinide in type 2 diabetic patients

Lawrence S. Cozma, MRCP, Stephen D. Luzio, PHD, Gareth J. Dunseath, BSC, Paul M. Underwood, MRCP and David R. Owens, MD, FRCP

Diabetes Research Unit, Academic Centre, Llandough Hospital, Penarth Cardiff, U.K

Address correspondence and reprint requests to Dr. Lawrence S. Cozma, Specialist Registrar in Diabetes and Endocrinology, Diabetes Research Unit, Academic Centre, Llandough Hospital, Penlan Road, Penarth Cardiff CF64 2XX, U.K. E-mail: sl.cozma{at}ntlworld.com

OBJECTIVE—To assess the effects of incremental doses of repaglinide on postprandial insulin and glucose profiles after a standard 500-kcal test meal.

RESEARCH DESIGN AND METHODS—Sixteen diet-treated Caucasians with type 2 diabetes (mean HbA1c 8.4%) were enrolled in this randomized, open-label, crossover trial. Subjects received 0.5, 1, 2, and 4 mg repaglinide or placebo in a random fashion, followed by a standard 500-kcal test meal on 5 separate study days, 1 week apart.

RESULTS—The insulinogenic index ({Delta}I30/{Delta}G30) and insulin area under the curve (AUC) from 0 to 30 min (AUC0–30) were higher with the 4-mg drug dose compared with the two lower doses and with 2 mg compared with 0.5 mg. On subgroup analysis, the incremental insulin responses were apparent only in the fasting plasma glucose (FPG) <9-mmol/l subgroup of subjects and not in the FPG >9-mmol/l subgroup. There was a significant dose-related increase in the late postprandial insulin secretion (insulin AUC120–240), which resulted in hypoglycemia in four subjects. Proinsulin-to-insulin ratios at 30 and 60 min improved with increasing doses of repaglinide; higher drug doses (2 and 4 mg) were more effective than the 0.5- and 1-mg doses.

CONCLUSIONS—Significant dose-related increases in early insulin secretion were found only in less advanced diabetic subjects. In advanced diabetic patients, only the maximum dose (4 mg) was significant compared with placebo. Better proinsulin-to-insulin processing was noted with increasing drug doses.

Abbreviations: AUC, area under the curve • FPG, fasting plasma glucose • PPG, postprandial glycemia


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.